Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers November 20, 2017
Pharmacy Choice - Pharmaceutical News - RhoVac AB participates in Nordic Life Science Days and at Aktiedagen - November 20, 2017

Pharmacy News Article

 9/13/17 - RhoVac AB participates in Nordic Life Science Days and at Aktiedagen

RhoVac AB ("RhoVac") will, as a natural step in the company's international communication, participate in Nordic Life Science Days in Malm, Sweden in September 2017. The company will also present at Aktiedagen in Gothenburg, Sweden later the same month.

RhoVac, a biotechnology company in clinical development, continues the increased international focus and participates in Nordic Life Science Days in Malm, Sweden on 13-14 September 2017. Nordic Life Science Days is the Nordic region's largest partner conference for the life science industry. Since its inception in 2013, the event has created a place for industry stakeholders to meet.
In addition, high-quality presenters provide insight into the latest trends in science and industry. Nordic Life Science Days attracts leading decision makers from biotechnology, pharma and med tech as well as finance, research, policy and supervisory authorities. The event gives RhoVac the opportunity to present the company and its cancer vaccine RV001 for a number of international pharmaceutical companies and other potential investors at individual meetings. RhoVac will participate with three representatives at this event.
In addition, RhoVac announces that CEO Anders Ljungqvist will present the company, status regarding development projects and the company's plans for 2017/2018 at Aktiedagen in Gothenburg, September 25, 2017, at 14.30 CET. Aktiedagen is held at Svenska Mssan, room H1, Mssans Gata 24, Gothenburg, Sweden.

For more information, please contact:

Anders Ljungqvist - VD, RhoVac AB

Phone: +45 4083 2365


About RhoVac AB

RhoVac AB conducts research and development of immunotherapeutic drugs. The company's main focus is the development of a therapeutic cancer vaccine with the potential to prevent or limit metastasis in cancer. RhoVac's first drug candidate has completed pre-clinical phase and clinical phase I / II study has started spring 2017. RhoVac has its head office at Medicon Village in Lund, Sweden. The research has been conducted since 2007 primarily at the University Hospital in Herlev, Denmark, by a world-class research team in its niche. RhoVac is listed on AktieTorget, Sweden, a Multilateral Trading Facility (MTF), since March 2016. The share is traded under the ticker RHOVAC. Read more at,c2345293

(c) 2017 Cision. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Nov 20: Obesity Management: Overview of Pharmacotherapy
Last Chance
Nov 21: Standards of Practice for Filling Controlled Substance Prescriptions in Florida
Nov 22: Medical Marijuana: Examining the Science, Not the Politics
Nov 27: Drug Diversion and the Law: Updates and Considerations
Nov 28: An Integrative Approach to Managing Arthritis
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement